Lipid nanoparticles for encapsulation of actives: Dermal & oral formulations

American Pharmaceutical Review

Volumn 10, Issue 6, 2007, Pages

  Keck, Cornelia M ^a   Hommoss, Aiman H ^a   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FENOFIBRATE; HALOFANTRINE; NANOMATERIAL; SOLID LIPID NANOPARTICLE; SURFACTANT; WATER;

AEROSOL; ATOMIC FORCE MICROSCOPY; BODY TEMPERATURE; CREAM; CRYSTAL; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; EMULSION; ENCAPSULATION; INDUSTRIAL PRODUCTION; LOTION; MARKET; PARTICLE SIZE; PHARMACY; REVIEW; SKIN;

EID: 55749108031     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Müller, R.H., Mäder, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of art, European Journal of Pharmaceutics and Biopharmaceutics, 2000. 50: p. 161-177.
2. Müller, R.H., Radtke, M., Wissing, S. A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Adv Drug Deliv Rev, 2002. 54 Suppl 1: p. S131-55.
3. Lucks, J.S., Müller, R.H., Medication vehicles made of solid lipid particles ( solid lipid nanospheres SLN), in EP0000605497. 1996: Germany.
4. Müller, R.H., Mäder, C., Wissing, S., Mittel mit UV-Strahlung absorbierender und/oder reflektierender Wirkung zum Schutz vor gesundheitschädhlicher UV-Strahlung und Stärkung der natürlichen Hautbarriere, in PCT/EP00/06534. 2000: Deutschland.
5. Müller, R.H., Wissing, S., Mäder, C., UV radiation reflecting or absorbing agents, protecting against harmful UV radiation and reinforcing the natural skin barrier, in US 6814959. 2004: USA.
6. Muller, R.H., Petersen, R.D., Hommoss, A., Pardeike, J., Nanostructured lipid carriers (NLC) in cosmetic dermal products, Adv Drug Deliv Rev, 2007. 59(6): p. 522-530.
7. Dingler, A., Fest Lipid-Nanopartikel als kolloidale Wirkstoffträ gersysteme zur dermalen Applikation. PhD thesis. 1998, Free University of Berlin: Berlin.
8. Hanafy, A., et al., Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug, Adv Drug Deliv Rev, 2007. 59(6): p. 419-26.
9. Muller, R.H., Dingler, A., Schneppe, T., Gohla, S., Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM), Handbook of Pharmaceutical Controlled Release Technology (Wise, D., ed.), 2000. 359-376.
10. Jenning, V., Gyslerb, A., Schaefer-Korting, M., Gohla, S., Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin, European Journal of Pharmaceutics and Biopharmaceutics, 1999. 49(Research paper): p. 211-218.
11. Wissing, S.,Müller, R.H., A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles, International Journal of Cosmetic Science, 2001. 23: p. 233-243.
12. Wissing, M., The influence of the crystallinity of lipid nanoparticles on their occlusive properties, International Journal of Pharmaceutics, 2002. 242: p. 377-379.
13. Wissing, S.A., Saupe, A., Müller, R. H., Nanostructured lipid carriers (NLC) for topical use- an overview, Euro Cosmetics, 2003. 5: p. 14-17.
14. Wissing, M., The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study, European Journal of Pharmaceutics and Biopharmaceutics, 2003. 56: p. 67-72.
15. Maia, C.S., Mehnert, W., Schafer-Korting, M., Solid lipid nanoparticles as drug carriers for topical glucocorticoids, Int J Pharm, 2000. 196(2): p. 165-167.
16. Wissing, S.A.,Muller, R.H., Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration, Journal of Controlled Release., 2002. 81(3): p. 225-33.
17. zur Mühlen, A., Schwarz, C., Mehnert, W., Solid lipid nanoparticles (SLN) for controlled drug delivery - Drug release and release mechanism, European Journal of Pharmaceutics and Biopharmaceutics, 1998. 45 (2): p. 149-155.
18. Sato, H., et al., Enhancement of the intestinal absorption of a cyclosporine derivative by milk fat globule membrane, Biol Pharm Bull, 1994. 17(11): p. 1526-8.
19. Kaukonen, A.M., Boyd, B.J., Charman, W.N., Porter, C.J.H., Drug Solubilization Behavior During in Vitro Digestion of Suspension Formulations of Poorly Water-Soluble Drugs in Triglyceride Lipids, Pharmaceutical Research, 2004. 21(2): p. 254-260.
20. Charman, S.A., et al., Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound, Pharm Res, 1992. 9(1): p. 87-93.
21. Strickley, R.G., Solubilizing excipients in oral and injectable formulations, Pharmaceutical Research, 2004. 21(2): p. 201-30.
22. Penkler, L.J., Muller, R.H., Runge, S.A., Ravelli, V., Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation, in United States Patent 6,551,619. 2003, Pharmatec International S.R.L.: USA.
23. Muller, R.H., et al., Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals, Int J Pharm, 2006. 317(1): p. 82-9.
24. Müller, R.H., et al., A new dimension in cosmetic products by nanostructured lipid carriers (NLC) technology, Eurocosmetics, 2007. 15: p. 32-37.